Genmab A/S (GMAB.KO, GMAB) Friday said the European Medicines
Agency’s Committee for Medicinal Products for Human Use recommended
expanded approval of Darzalex in a form of multiple myeloma.
The Copenhagen biotechnology company said the recommendation covers
Darzalex in combination with lenalidomide and dexamethasone for newly
diagnosed adults with multiple myeloma who are ineligible for autologous
stem-cell transplant.
Genmab’s licensing partner, Johnson & Johnson’s (JNJ) Janssen
Biotech Inc. unit, had filed for approval of the new indication in
March. Janssen has an exclusive license to develop, manufacture and
commercialize Darzalex under an August 2012 agreement with Genmab.
The European Commission, which generally follows the CHMP’s
recommendations, is expected to make a final decision in the coming
months, Genmab said.
Darzalex is already approved in the European Union for several
indications in multiple myeloma, a cancer that forms in a type of white
blood cells called plasma cells and causes cancer cells to accumulate in
the bone marrow.
https://www.marketscreener.com/JOHNSON-JOHNSON-4832/news/Johnson-Johnson-Genmab-Janssen-Get-CHMP-Positive-Option-for-Expanded-Darzalex-Use-29416115/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.